Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
29
HEPA Quote, Financials, Valuation and Earnings
Last price:
$0.07
Seasonality move
:
-6.82%
Day range:
$0.07 - $0.07
52-week range:
$0.03 - $36.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.44x
Volume:
6.2K
Avg. volume:
14.8K
1-year change:
-99.73%
Market cap:
$713.5K
Revenue:
--
EPS (TTM):
-$13.40
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HEPA
Hepion Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HEPA
Hepion Pharmaceuticals, Inc.
|
$0.07 | -- | $713.5K | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.57 | $0.85 | $575.9M | 7.68x | $0.80 | 0% | 8.88x |
|
NNVC
NanoViricides, Inc.
|
$1.20 | $6.50 | $21.6M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.83 | $2.00 | $682.6K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.20 | $7.00 | $6.8M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HEPA
Hepion Pharmaceuticals, Inc.
|
6.06% | 4.304 | 9.55% | 6.68x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HEPA
Hepion Pharmaceuticals, Inc.
|
-- | -$527.9K | -305.96% | -524.07% | -- | -$446K |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Hepion Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns HEPA or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Hepion Pharmaceuticals, Inc.'s net margin of -255.85%. Hepion Pharmaceuticals, Inc.'s return on equity of -524.07% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital HEPAHepion Pharmaceuticals, Inc.-- -$0.04 $3.5M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About HEPA or NBY?
Hepion Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 2307592.31%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -81.4%. Given that Hepion Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Hepion Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HEPAHepion Pharmaceuticals, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is HEPA or NBY More Risky?
Hepion Pharmaceuticals, Inc. has a beta of 2.067, which suggesting that the stock is 106.656% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock HEPA or NBY?
Hepion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Hepion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HEPA or NBY?
Hepion Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Hepion Pharmaceuticals, Inc.'s net income of -$472.5K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Hepion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals, Inc. is -- versus 8.88x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HEPAHepion Pharmaceuticals, Inc.-- -- -- -$472.5K NBYNovaBay Pharmaceuticals, Inc.8.88x 7.68x $521K -$1.3M
-
Which has Higher Returns HEPA or NNVC?
NanoViricides, Inc. has a net margin of -- compared to Hepion Pharmaceuticals, Inc.'s net margin of --. Hepion Pharmaceuticals, Inc.'s return on equity of -524.07% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital HEPAHepion Pharmaceuticals, Inc.-- -$0.04 $3.5M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About HEPA or NNVC?
Hepion Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 2307592.31%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 441.67%. Given that Hepion Pharmaceuticals, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Hepion Pharmaceuticals, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HEPAHepion Pharmaceuticals, Inc.0 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is HEPA or NNVC More Risky?
Hepion Pharmaceuticals, Inc. has a beta of 2.067, which suggesting that the stock is 106.656% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock HEPA or NNVC?
Hepion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HEPA or NNVC?
Hepion Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Hepion Pharmaceuticals, Inc.'s net income of -$472.5K is higher than NanoViricides, Inc.'s net income of -$1.8M. Notably, Hepion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HEPAHepion Pharmaceuticals, Inc.-- -- -- -$472.5K NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns HEPA or OGEN?
Oragenics, Inc. has a net margin of -- compared to Hepion Pharmaceuticals, Inc.'s net margin of --. Hepion Pharmaceuticals, Inc.'s return on equity of -524.07% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital HEPAHepion Pharmaceuticals, Inc.-- -$0.04 $3.5M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About HEPA or OGEN?
Hepion Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 2307592.31%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 141.11%. Given that Hepion Pharmaceuticals, Inc. has higher upside potential than Oragenics, Inc., analysts believe Hepion Pharmaceuticals, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HEPAHepion Pharmaceuticals, Inc.0 0 0 OGENOragenics, Inc.1 0 0 -
Is HEPA or OGEN More Risky?
Hepion Pharmaceuticals, Inc. has a beta of 2.067, which suggesting that the stock is 106.656% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock HEPA or OGEN?
Hepion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HEPA or OGEN?
Hepion Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Hepion Pharmaceuticals, Inc.'s net income of -$472.5K is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Hepion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HEPAHepion Pharmaceuticals, Inc.-- -- -- -$472.5K OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns HEPA or PTN?
Palatin Technologies has a net margin of -- compared to Hepion Pharmaceuticals, Inc.'s net margin of --. Hepion Pharmaceuticals, Inc.'s return on equity of -524.07% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HEPAHepion Pharmaceuticals, Inc.-- -$0.04 $3.5M PTNPalatin Technologies-- -- -- -
What do Analysts Say About HEPA or PTN?
Hepion Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 2307592.31%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Hepion Pharmaceuticals, Inc. has higher upside potential than Palatin Technologies, analysts believe Hepion Pharmaceuticals, Inc. is more attractive than Palatin Technologies.
Company Buy Ratings Hold Ratings Sell Ratings HEPAHepion Pharmaceuticals, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is HEPA or PTN More Risky?
Hepion Pharmaceuticals, Inc. has a beta of 2.067, which suggesting that the stock is 106.656% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock HEPA or PTN?
Hepion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HEPA or PTN?
Hepion Pharmaceuticals, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Hepion Pharmaceuticals, Inc.'s net income of -$472.5K is higher than Palatin Technologies's net income of --. Notably, Hepion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HEPAHepion Pharmaceuticals, Inc.-- -- -- -$472.5K PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns HEPA or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Hepion Pharmaceuticals, Inc.'s net margin of --. Hepion Pharmaceuticals, Inc.'s return on equity of -524.07% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital HEPAHepion Pharmaceuticals, Inc.-- -$0.04 $3.5M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About HEPA or TOVX?
Hepion Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 2307592.31%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3349.98%. Given that Hepion Pharmaceuticals, Inc. has higher upside potential than Theriva Biologics, Inc., analysts believe Hepion Pharmaceuticals, Inc. is more attractive than Theriva Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HEPAHepion Pharmaceuticals, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is HEPA or TOVX More Risky?
Hepion Pharmaceuticals, Inc. has a beta of 2.067, which suggesting that the stock is 106.656% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock HEPA or TOVX?
Hepion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HEPA or TOVX?
Hepion Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Hepion Pharmaceuticals, Inc.'s net income of -$472.5K is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Hepion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HEPAHepion Pharmaceuticals, Inc.-- -- -- -$472.5K TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 4.21% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 1.01% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.58% over the past day.
